RAPT Therapeutics Inc

詳細情報 RAPT Therapeutics Inc 企業名

RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.

企業情報

企業コードRAPT

会社名RAPT Therapeutics Inc

上場日Oct 31, 2019

設立日2015

最高経営責任者「CEO」Dr. Brian Wong, M.D., Ph.D.

従業員数68

証券種類Ordinary Share

決算期末Oct 31

本社所在地561 Eccles Ave

都市SOUTH SAN FRANCISCO

証券取引所NASDAQ Global Market Consolidated

国United States of America

郵便番号94080

電話番号16504899000

ウェブサイトhttps://rapt.com/

企業コードRAPT

上場日Oct 31, 2019

設立日2015

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Scott N. Braunstein, M.D.

Independent Director

--

Dr. Ashley Dombkowski, Ph.D.

Independent Director

--

Dr. Michael F. Giordano, M.D.

Independent Director

--

Dr. William (Bill) Ho, M.D., Ph.D.

Chief Medical Officer

--

Dr. Mary Ann Gray, Ph.D.

Independent Director

--

Ms. Lori Lyons-Williams

Independent Chairman of the Board

--

Dr. Brian Wong, M.D., Ph.D.

President, Chief Executive Officer, Director

--

Dr. Dirk Brockstedt, Ph.D.

Chief Scientific Officer

--

Mr. Rodney K. B. Young

Chief Financial Officer

--

Ms. Linda Kozick

Independent Director

--

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Scott N. Braunstein, M.D.

Independent Director

--

Dr. Ashley Dombkowski, Ph.D.

Independent Director

--

Dr. Michael F. Giordano, M.D.

Independent Director

--

Dr. William (Bill) Ho, M.D., Ph.D.

Chief Medical Officer

--

Dr. Mary Ann Gray, Ph.D.

Independent Director

--

Ms. Lori Lyons-Williams

Independent Chairman of the Board

--

収益内訳

データなし

データなし

事業別

地域別

データなし

株主

更新時刻: Sat, May 17

株主統計

種類

株主統計

比率

Medicxi Ventures (UK) LLP

16.90%

OrbiMed Advisors, LLC

9.93%

TCG Crossover Management, LLC

9.90%

Foresite Capital Management, LLC

9.45%

RTW Investments L.P.

8.89%

Other

44.94%

株主統計

比率

Medicxi Ventures (UK) LLP

16.90%

OrbiMed Advisors, LLC

9.93%

TCG Crossover Management, LLC

9.90%

Foresite Capital Management, LLC

9.45%

RTW Investments L.P.

8.89%

Other

44.94%

種類

株主統計

比率

Investment Advisor/Hedge Fund

23.39%

Private Equity

22.72%

Hedge Fund

21.09%

Venture Capital

17.98%

Investment Advisor

13.44%

Research Firm

0.60%

Individual Investor

0.44%

Bank and Trust

0.09%

Family Office

0.09%

Other

0.15%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

295

16.51M

99.85%

-973.03K

2025Q1

309

29.14M

109.47%

+11.54M

2024Q4

309

140.52M

106.54%

+100.36M

2024Q3

304

31.22M

87.82%

-13.95M

2024Q2

305

33.18M

93.85%

-9.52M

2024Q1

295

33.76M

95.60%

-5.47M

2023Q4

282

36.46M

106.02%

-3.53M

2023Q3

281

36.40M

105.98%

-3.26M

2023Q2

295

35.63M

103.77%

-4.21M

2023Q1

301

34.71M

101.29%

-3.14M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Medicxi Ventures (UK) LLP

2.79M

16.9%

--

Mar 31, 2025

OrbiMed Advisors, LLC

1.64M

9.93%

--

Mar 31, 2025

TCG Crossover Management, LLC

1.64M

9.9%

-5.63K

-0.34%

Mar 31, 2025

Foresite Capital Management, LLC

1.56M

9.45%

--

Mar 31, 2025

RTW Investments L.P.

1.47M

8.89%

--

Mar 31, 2025

BVF Partners L.P.

1.15M

6.98%

--

Mar 31, 2025

The Vanguard Group, Inc.

1.03M

6.26%

+668.30K

+182.32%

Mar 31, 2025

Redmile Group, LLC

809.41K

4.89%

--

Mar 31, 2025

Deep Track Capital LP

751.42K

4.54%

--

Mar 31, 2025

Adar1 Capital Management LLC

746.35K

4.51%

+599.56K

+408.45%

Mar 31, 2025

詳細を見る

8.160USD

RAPT Therapeutics Inc

8.160

概要

企業名